



## Variation Agreement relating to Supervised Consumption (Local Enhanced Service) Service Level Agreement.

**THIS AGREEMENT** is made on 30.11.18 between; CGL Inspire East Substance Misuse Services – Inspire Blackburn with Darwen

(1) **change, grow, live (CGL)**, a registered charity in England and Wales (1079327). Company Registration Number 3861209 (England and Wales) whose registered offices is at Third Floor, Tower Point, 44 North Road, Brighton, BN1 1YR

And

(2) **Registered Pharmacist delivering a Supervised Consumption Service – Name**

### **Contract Variation**

#### **Prescription change from generic buprenorphine to Espranor®**

In view of recent buprenorphine supply and price fluctuations it has been decided to review service users that are prescribed buprenorphine tablets and where appropriate change them to Espranor.

The intended switch to Espranor will commence from 3.12.2018 in a phased approach, with service users being reviewed individually by a prescriber and any changes made from the next prescription. This will provide sufficient time for pharmacies to manage current generic buprenorphine stock and order Espranor.

As part of this switch to Espranor we will be sending out Patient Information Leaflets with the new prescriptions and request that pharmacies hand these out to service users when they attend for their medication.

Not all service users will be suitable to change to Espranor and will remain on buprenorphine tablets.

#### **Buprenorphine substitution – Espranor®**

Espranor contains buprenorphine. It is an oral lyophilisate which is available as a 2mg and 8mg formulation. The lyophilisates are administered by placing on the tongue and dissolving rapidly. This is different to buprenorphine sublingual tablets which are placed under the tongue and take longer to dissolve.

Espranor has a higher bioavailability than generic buprenorphine. Service users will be reviewed individually to ensure they are transferred on to an appropriate dose, with follow up shortly after to make any necessary dose adjustments.

Espranor should only be handled with dry fingers. Service users should be advised not to swallow for 2 minutes following administration, and should not eat or drink for 5 minutes following administration. This will ensure the service user absorbs the full dose of medication.

### **Supervised consumption**

The time taken to supervise consumption of Espranor will be less than for generic buprenorphine.

Supervised consumption of Espranor will be paid at the same rate as for buprenorphine supervised consumption

**Supply of Espranor**

Espranor is available from 4 wholesalers:

Wholesaler	Contact	Order codes
AAH	0344 561 8899	2mg: ESP5P 8mg: ESP6L
Alliance	020 8391 2323	2mg: 4036778 8mg: 4036786
DE Pharmaceuticals	01302 552941	
Phoenix	01928 750 500	

**IT IS AGREED AS FOLLOWS**

1. This agreement (the "Variation") is supplemental to a contract dated 2018/2019 Supervised Consumption Service Level Agreement.
2. The parties have agreed to vary the Contract as set out in Schedule 1 and the Variation shall be read, construed and take effect as if the amendments set out in the Schedule had been made in the Contract.
3. Save as varied in accordance with clause 2, the Contract shall remain in full force and effect.

IN WITNESS of which this Agreement has been duly executed by the parties.

Executed on behalf of change, grow, live (CGL) by:

Signature:

Name:

Role:

Date:

Executed on behalf of **SUBCONTRACTOR** by:

Signature:

Name:

Role:

Date:

**Schedule 1 – Contract Variations**

<b>Clause Number</b>	<b>Variation</b>